杭企嘉因生物冲刺港股IPO

Group 1 - The core viewpoint of the article is that gene therapy is becoming a central focus for companies, with Hangzhou Jiayin Biotechnology Co., Ltd. officially submitting its prospectus to the Hong Kong Stock Exchange [1] - Jiayin Biotechnology, established in 2019, specializes in the development of gene therapies and oligonucleotide drugs, utilizing a dual technology platform system consisting of AAVarta and SODA [1] - The company’s research covers a wide range of diseases, including neurological disorders, ophthalmic diseases, and various hereditary and chronic conditions, resulting in a diversified product pipeline [1] Group 2 - Jiayin Biotechnology currently has 10 candidate products in development, with 4 of them already in clinical stages [2] - The core product EXG001-307, targeting SMA1 type, is set to enter Phase III clinical trials in the second half of this year and is considered the potential best-in-class candidate for SMA1 treatment in China [2] - The funds raised from the IPO will primarily be used for the further development of core products EXG001-307, key products EXG102-031 and EXG202, as well as to enhance the core technology platform and support daily operations and business expansion [2]